Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab in Factor XII-associated Cold Autoinflammatory Syndrome
NCT04278885Phase 2Active, not recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanadelumab in Factor XII-associated cold autoinflammatory syndrome (FACAS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in total disease activity score as assessed by daily health assessment form (DHAF) questionnaire at 12 weeks. Started Oct 2020; status: active, not recruiting.
02
Drugs
lanadelumab
03
Conditions
Factor XII-associated cold autoinflammatory syndrome (FACAS)
Beyond the preview
Go deeper on NCT04278885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278885.